Stefan Agewall

Oslo University Hospital

Norway

Research Interests

Explore related searches

Professors in Norway

Contact this professor

ORCID

Google Scholar

Articles (20)

Short-term exposure to ambient temperature variability and myocardial infarction hospital admissions: A nationwide case-crossover study in Sweden.

Article Link

Year:

2025

Antiplatelet treatment in different clinical settings

Article Link

Year:

2025

Our knowledge about atrial fibrillation steadily increases

Article Link

Year:

2025

We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists

Article Link

Year:

2025

Bleeding and thrombosis

Article Link

Year:

2025

Lipid treatment

Article Link

Year:

2025

Prevention is the key

Article Link

Year:

2025

Update on antithrombotic therapy and body mass. A Clinical consensus Statement of the ESC Working Group on Cardiovascular Pharmacotherapy and the ESC Working Group on Thrombosis

Article Link

Year:

2024

Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI

Article Link

Year:

2024

Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic

Article Link

Year:

2024

Focus on prevention in diabetes mellitus and lipid disorder

Article Link

Year:

2023

A tailor-made suit always fits best

Article Link

Year:

2023

Fibrates: one more lost paradise in lipid treatment

Article Link

Year:

2023

Focus on lipid treatment

Article Link

Year:

2023

Toward personalized medicine for cardiovascular pharmacotherapy

Article Link

Year:

2022

Pharmacological treatment of CVD

Article Link

Year:

2022

Future of European Heart Journal Cardiovascular Pharmacotherapy

Article Link

Year:

2022

To treat or not to treat

Article Link

Year:

2022

Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events

Article Link

Year:

2022

Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding

Article Link

Year:

2022

Collaborators (7)

Elisabetta Cerbai

Professor

Università degli Studi di Napoli Federico II

ITALY

Petter Ljungman

Karolinska Institutet

SWEDEN

Péter Ferdinandy

HUNGARY

Dan Atar

Professor of Cardiology and Head of Research

Oslo University Hospital

NORWAY

Christina Christersson

SWEDEN

Bruna Gigante

Karolinska Institutet

SWEDEN

Jeroen de Bont

Karolinska Institutet

SWEDEN

Stefan Agewall

Research Interests

Explore related searches

Contact this professor

Articles (20)

Short-term exposure to ambient temperature variability and myocardial infarction hospital admissions: A nationwide case-crossover study in Sweden.

Antiplatelet treatment in different clinical settings

Our knowledge about atrial fibrillation steadily increases

We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists

Bleeding and thrombosis

Lipid treatment

Prevention is the key

Update on antithrombotic therapy and body mass. A Clinical consensus Statement of the ESC Working Group on Cardiovascular Pharmacotherapy and the ESC Working Group on Thrombosis

Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI

Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic

Focus on prevention in diabetes mellitus and lipid disorder

A tailor-made suit always fits best

Fibrates: one more lost paradise in lipid treatment

Focus on lipid treatment

Toward personalized medicine for cardiovascular pharmacotherapy

Pharmacological treatment of CVD

Future of European Heart Journal Cardiovascular Pharmacotherapy

To treat or not to treat

Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events

Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding

Collaborators (7)

Elisabetta Cerbai

Petter Ljungman

Péter Ferdinandy

Dan Atar

Christina Christersson

Bruna Gigante

Jeroen de Bont

How do I reach out?

Meet Kite AI